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More Questions Than Answers?We welcome the paper by Drakos et al. (1), who investigated the
longitudinal effects of continuous-ﬂow left ventricular assist device
(LVAD) unloading on cardiac structure and function. The authors
concluded that younger patients and those with earlier LVAD
implantation since onset of heart failure achieved the largest struc-
tural improvements and the most favorable functional recovery (1).
Nonetheless, the report raises more questions than those it purports
to address.
First, neither the paper nor the supplementary material describes
which devices were actually used as LVADs. As each device has its
own unique characteristics and risk–beneﬁt proﬁle that may
translate on the individual response to cardiac unloading (2), we
recommend that the authors provide comparative data testing
whether any speciﬁc device was associated with better or worse
results than the others.
Second, it is well established that several pathophysiological
mechanisms interplay in a complex, yet hitherto incompletely
determined, fashion with the beneﬁts of LVAD. Speciﬁcally,
important mediators in the recovery of cardiac function after LVAD
implantation should include proapoptotic genes such as caspases;
microribonucleic acid; tumor necrosis factor-a, with its essential
regulation of maladaptive cardiac remodeling; and insulin-like
growth factor-1 (3,4). Furthermore, the demonstration that car-
diomyocytes are not terminally differentiated cells with the capacity
to re-enter the cell cycle even in LVAD models strongly suggests
that they might also be involved in determining which patients do
or do not respond favorably to LVAD therapy in routine clinical
practice (5–7).
However, no comprehensive and uniﬁed appraisal of the afore-
mentioned pathophysiological mechanisms has been performed
before in a suitably large cohort of subjects treated with LVAD
support. We thus believe that it is crucial to further investigate
the cluster of metabolic, neuroendocrine, and molecular markers
and chemokines for a “full biomolecular proﬁle” of patients
receiving LVAD (8), which is expected to provide a more precise
diagnostic and prognostic tool to guide the choice and timing
of LVAD implantation as well as to monitor the impact of LVAD
on cardiac remodeling and recovery well after its deployment.
Indeed, the precise characterization and modulation of molecular
pathways and resident stem cells would allow the optimization of
left ventricular response aiming for a more satisfactory cardiac
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in Chronic Heart Failure
More Questions Than Answers?
We appreciate the interest that Dr. Marullo and colleagues have
taken in our study (1). Previous data on left ventricular assist device
(LVAD)-induced myocardial recovery have suggested that the
patient’s age and duration of heart failure history may be associated
with successful recovery (2,3). In our study, patients who achieved
a meaningful functional and structural myocardial recovery were
younger (median age 48 years) and had a shorter duration of heart
failure symptoms (median 1 year), agreeing with such observations.
Comparative studies between pulsatile and continuous ﬂow devices
have shown differences in the degree of left ventricular (LV)
unloading, hemodynamic proﬁle, and their potential to induce
myocardial recovery, as we have recently summarized (4). However,
such hemodynamic disparities are not apparent among different
types of the continuous-ﬂow LVAD (5), which was the type of
device evaluated in our study. The assist devices implanted in our
study included 57 (71%) HeartMate II (Thoratec, Pleasanton,
California), 10 (13%) HVAD (HeartWare International,
